A Phase 3 interventional study of Dotarem and Time of Flight in Renal Disease, sponsored by Guerbet. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-26.
Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 416 studies in Kidney Diseases with a site in United States — 64 open to participants now, 92 under way, 15 of them phase 3. Kidney Diseases · United States.
Among the 416 studies in Kidney Diseases with a site in United States, this one is the 272nd largest by enrollment of the 318 interventional ones that give a count, is one of 18 that started in 2009, is one of 59 in phase 3, and was the 115th registered.
970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.
Browse Kidney Diseases studies →64 of the 416 studies in Kidney Diseases with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
Geisinger Clinic · Sites in United States
Ages 18+
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 18–115
Pediatric Nephrology Research Consortium · Sites in United States
Ages up to 18
Novartis Pharmaceuticals · Sites in United States, China, Colombia and 5 more countries
Ages 2–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
416 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 87 · Phase 3 63 · Phase 4 24
First in 1976; this study’s year is marked. 18 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 64 across 647 interventional studies indexed under Kidney Diseases.
Median enrollment 50 across the 318 interventional studies, 226 across the 93 observational. Of the 296 that completed or were terminated, 126 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
166 of 416 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 1 study filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
27 of the studies in Kidney Diseases with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT06087835Phase 3AstraZenecaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | 2027-02-18 |
| NCT05696613Phase 3Cerium Pharmaceuticals, Inc.A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy | 2027-04-01 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT05153967Vanderbilt University Medical CenterCooperative Assessment of Late Effects for SCD Curative Therapies | 2026-11 |
Add all 27 to your calendar (.ics) → With an account.
Among the 416 studies in Kidney Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.
Each participant will undergo first a TOF MRA followed by a Dotarem-enhanced MRA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each subject will receive one injection of Dotarem 0.2ml/kg.
Drug: Dotarem
Each subject will undergo a TOF Magnetic Resonance Angiography
Other: Time of Flight
Each subject will receive one injection of Dotarem 0.2ml/kg
Also known as: gadoteric acid, gadoterate meglumine
Each subject will undergo a TOF MRA
Percent of Non Assessable Renal Artery Segments
For each examination (TOF and Dotarem-enhanced MRA) the percent of non-assessable segments will be compared
Time frame: 1 to 7 days
The recruitment started in Sept 2009 and stopped in February 2010. Radiology departments from hospital or private practices were participating.
| Milestone | TOF Followed by Dotarem-enhanced MRA |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
| Milestone | TOF Followed by Dotarem-enhanced MRA |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
For each examination (TOF and Dotarem-enhanced MRA) the percent of non-assessable segments will be compared
| percentage of non-assessable segments | Dotarem-enhanced MRA | Time-Of-Flight MRA |
|---|---|---|
| Percent of Non Assessable Renal Artery Segments | 25 | 20 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dotarem | — | 0/10 (0%) | 4/10 (40%) |
| Time Of Flight | — | 0/10 (0%) | 0/10 (0%) |
| Event | Dotarem | Time Of Flight |
|---|---|---|
| Injection site painGeneral disorders | 2/10 | 0/10 |
| Injection site inflammationGeneral disorders | 1/10 | 0/10 |
| Abdominal painGastrointestinal disorders | 1/10 | 0/10 |
| DiarrheaGastrointestinal disorders | 1/10 | 0/10 |
| Age, Categorical(Participants) | TOF Followed by Dotarem-enhanced MRA |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 6 |
| Age, Continuous(years) | TOF Followed by Dotarem-enhanced MRA |
|---|---|
| Mean | 59 ± 16 |
| Sex: Female, Male(Participants) | TOF Followed by Dotarem-enhanced MRA |
|---|---|
| Female | 9 |
| Male | 4 |
| Region of Enrollment(participants) | TOF Followed by Dotarem-enhanced MRA |
|---|---|
| United States | 7 |
| Canada | 6 |
The record gives a start of Sep 2009, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine